SAHA increases chaperone expression and reduces Z-alpha-1-antitrypsin polymers in a patient specific iPSC-based liver model for alpha-1-antitrypsin deficiency

This study utilizes a patient-specific iPSC-derived liver model to demonstrate that the drug SAHA reduces toxic Z-alpha-1-antitrypsin polymers by upregulating heat-shock protein chaperones, thereby mitigating ER stress in alpha-1-antitrypsin deficiency.

The Gist

The Big Picture: A Factory with a Broken Conveyor Belt

Imagine the liver as a massive, high-tech factory. Its main job is to produce a specific product called Alpha-1-Antitrypsin (AAT). Think of AAT as a "bodyguard" protein that travels through your blood to protect your lungs from being chewed up by inflammation (specifically, by an enzyme called neutrophil elastase).

In people with Alpha-1-Antitrypsin Deficiency (AATD), there is a typo in the factory's blueprint (the DNA). This typo causes the factory to make a defective version of the bodyguard, called the "Z" mutant.

Here is the problem:

1. The Jam: Because of the typo, the "Z" bodyguards get confused and fold up incorrectly. Instead of leaving the factory to protect the lungs, they get stuck in the factory's loading dock (the cell's Endoplasmic Reticulum).
2. The Pile-Up: These stuck proteins clump together into giant, sticky balls (polymers).
3. The Damage: The factory gets clogged. The loading dock is overwhelmed, the workers (the cell) get stressed out, and eventually, the factory starts to break down, leading to liver disease.

The Experiment: Building a "Mini-Liver" in a Dish

For a long time, scientists tried to study this using mice or simple cell lines, but those models were like trying to fix a Ferrari engine using a toy car. They didn't quite match the real human problem.

In this study, the researchers did something clever:

• They took skin cells from real AATD patients.
• They "rewound" these cells to turn them into iPSCs (Induced Pluripotent Stem Cells). Think of these as "blank slates" or "clay" that can be molded into anything.
• They then guided this clay to become Hepatocyte-Like Cells (HLCs). Essentially, they built a mini-liver in a petri dish that carries the exact same genetic typo as the patient.

The Result: They successfully created a working model. The mini-livers behaved exactly like the real thing: they made the defective "Z" proteins, and those proteins clumped up inside the cells, just like in the patients.

The Solution: The "Stress Relievers"

Now that they had a perfect model, the researchers wanted to see if they could unclog the factory. They tested four different "cleaning agents" (drugs) to see if they could help the factory either:

1. Fix the folding of the proteins so they leave the factory.
2. Clean up the pile-ups so the factory doesn't get stressed.

They tested:

• Carbamazepine (CBZ): A drug usually used for seizures, known to help cells clean up trash.
• SAHA: A drug that acts like a "volume knob" for the cell's internal helpers.
• Kifunensine (KIF) & Cysteamine (CYS): Other compounds that try to help proteins fold correctly.

The Winners: SAHA and CBZ

The experiment showed that SAHA and CBZ were the clear winners.

• What they did: When they added these drugs to the mini-livers, the giant clumps of "Z" proteins disappeared. The factory got unclogged!
• How SAHA worked (The Star Performer): SAHA is a special type of drug. Imagine the cell has a team of Helpers (called Chaperones or Heat-Shock Proteins). Their job is to grab misfolded proteins and help them fold correctly.
  • In the sick cells, these Helpers were overwhelmed and tired.
  • SAHA turned up the volume. It told the cell, "Make more Helpers! Get more of them on the job!"
  • With more Helpers available, the "Z" proteins were either fixed or broken down efficiently, reducing the toxic pile-up.

Why This Matters

This study is a big deal for three reasons:

1. A Better Test Tube: They proved that growing a patient's own liver cells in a dish is a fantastic way to test new drugs. It's like having a "digital twin" of the patient's liver to try out cures without risking the patient's health.
2. New Hope for Treatment: They found that SAHA (a drug already approved for other uses) could significantly reduce the toxic clumps in these cells. This suggests it could be repurposed to treat AATD patients.
3. Understanding the Stress: They discovered that the disease isn't just about the bad protein; it's about the cell being stressed out. By helping the cell manage that stress (by boosting the Helpers), we can stop the liver damage before it starts.

The Bottom Line

Think of AATD as a factory clogged with sticky, misfolded toys. This study built a miniature version of that factory to test solutions. They found that a drug called SAHA acts like a super-charged cleaning crew, bringing in more helpers to clear the jam and keep the factory running smoothly. This opens the door to new treatments that could stop liver damage in people with this genetic condition.

Technical Summary

1. Problem Statement

Alpha-1-antitrypsin deficiency (AATD) is a severe genetic disorder caused primarily by the Pi*Z mutation (Glu342Lys substitution) in the SERPINA1 gene. This mutation leads to the misfolding and polymerization of the alpha-1-antitrypsin (AAT) protein within the endoplasmic reticulum (ER) of hepatocytes.

• Pathophysiology: The accumulation of misfolded ZAAT polymers triggers ER stress, activates the unfolded protein response (UPR), and can lead to liver cirrhosis and hepatocellular carcinoma (HCC), in addition to lung emphysema.
• Current Limitations: Existing models for studying AATD have significant drawbacks:
  • Mouse models: Require complex genetic deletions of endogenous mouse serpins to reveal lung phenotypes, and liver phenotypes often require human ZAAT overexpression, which does not fully mimic the human disease context.
  • Immortalized cell lines: Often require artificial overexpression of ZAAT and exhibit abnormal gene expression profiles that do not reflect human physiology.
• Therapeutic Gap: While several small molecules (e.g., Carbamazepine, SAHA) have shown promise in reducing ZAAT aggregates in previous studies, their efficacy and mechanisms need validation in a more physiologically relevant human model.

2. Methodology

The authors developed a patient-specific induced pluripotent stem cell (iPSC) model to study AATD and screen potential therapeutics.

• Cell Lines:
  • Patient-derived: Two iPSC lines from homozygous Pi*ZZ AATD patients (UKA4, UKA6) with severe liver phenotypes.
  • Control: One iPSC line from a healthy donor (UM51).
• Differentiation Protocol: All lines were differentiated into Hepatocyte-like cells (HLCs) using a three-step optimized protocol (Definitive Endoderm $\rightarrow$ Hepatic Endoderm $\rightarrow$ HLC) over 19 days.
• Drug Screening: Patient-derived HLCs were treated for 48 hours with four candidate compounds previously studied in other models:
  • Carbamazepine (CBZ): Autophagy enhancer.
  • Suberoylanilide hydroxamic acid (SAHA): Histone deacetylase inhibitor (HDACi).
  • Kifunensine (KIF): $\alpha$-mannosidase I inhibitor.
  • Cysteamine (CYS): Protein disulfide isomerase inhibitor.
• Analytical Techniques:
  • Immunocytochemistry (ICC) & Western Blot: To quantify ZAAT polymer accumulation and AAT levels in soluble vs. insoluble fractions.
  • Functional Assays: CYP3A4/CYP2D6 activity and Indocyanine Green (ICG) uptake/release to confirm hepatocyte maturity.
  • Bulk RNA-Sequencing (NGS): To analyze global transcriptomic changes, Gene Ontology (GO) terms, and KEGG pathways between control and patient cells, and in response to drug treatment.
  • qRT-PCR: To validate specific gene expression changes (e.g., Heat Shock Proteins).

3. Key Contributions

• Validation of iPSC-HLC Model: Demonstrated that iPSCs from AATD patients differentiate into functional HLCs that recapitulate the disease phenotype (ZAAT polymer accumulation) without requiring artificial overexpression.
• Transcriptomic Profiling: Provided a comprehensive map of the metabolic and signaling dysregulation in AATD-derived HLCs compared to healthy controls, highlighting specific stress pathways.
• Mechanistic Insight into SAHA: Identified that SAHA reduces ZAAT polymers not just by enhancing degradation, but by upregulating the expression of Heat Shock Proteins (HSPs), specifically the HSP70 family, thereby improving protein folding homeostasis.
• Discovery of Peroxisome Pathway Link: Revealed that SAHA treatment downregulates peroxisome proliferator pathways, which were previously identified as highly correlated with ZAAT load in patient livers.

4. Key Results

A. Model Characterization

• Differentiation: All cell lines (control and patient) differentiated efficiently into HLCs, expressing markers like HNF4$\alpha$, Albumin (ALB), and CYP3A4.
• Phenotype Confirmation: Patient-derived HLCs showed significant accumulation of ZAAT polymers (visible as clump-like structures via ICC) compared to the homogeneous distribution in control cells.
• Transcriptomic Differences:
  • Up-regulated in AATD: Genes associated with organelles, intracellular membranes, mitochondria, ER, and Golgi apparatus (indicating high cellular stress and energy demand).
  • Down-regulated in AATD: Metabolic pathways (amino acid biosynthesis) and signaling pathways (MAPK, cAMP, calcium). Crucially, bile secretion pathways were downregulated, mirroring the cholestatic phenotype seen in pediatric AATD patients.
  • HSP Clustering: Control and patient transcriptomes formed distinct clusters based on Heat Shock Protein (HSP) gene expression.

B. Drug Treatment Efficacy

• SAHA and CBZ: Both compounds significantly reduced ZAAT polymer load in patient-derived HLCs:
  • SAHA: Reduced ZAAT by ~77% (UKA6) and ~64% (UKA4).
  • CBZ: Reduced ZAAT by ~52% (UKA6) and ~54% (UKA4).
• KIF and CYS: Kifunensine showed reduction only in one patient line (UKA4), while Cysteamine showed no significant effect at the tested concentrations.
• Protein Levels: SAHA treatment also reduced total AAT protein levels (suggesting a feedback loop on synthesis) and reduced the insoluble protein fraction (including $\beta$-Actin), indicating a global effect on protein aggregation.

C. Mechanism of Action (SAHA)

• HSP Upregulation: RNA-seq and qPCR confirmed that SAHA treatment significantly upregulated HSP70 family members (including HSPA5/GRP78, HSPA1A, HSPA1B).
• Protein vs. mRNA: While HSPA5 mRNA increased, GRP78 protein levels did not change significantly in Western blots. The authors suggest this is due to post-translational modifications regulating GRP78 activity rather than abundance.
• Peroxisome Pathway: SAHA significantly downregulated genes in the peroxisome proliferator pathway (e.g., AGXT, BAAT, HAO2). This pathway was previously linked to ZAAT load, suggesting SAHA targets a key disease driver.

5. Significance

• Therapeutic Potential: The study validates SAHA as a potent candidate for AATD therapy. Its dual mechanism—enhancing chaperone-mediated folding (via HSPs) and modulating metabolic pathways (peroxisomes)—offers a promising strategy to reduce toxic polymer accumulation.
• Model Utility: The iPSC-derived HLC model is proven to be a robust, patient-specific platform for drug screening and disease modeling, overcoming the limitations of mouse models and immortalized cell lines.
• Clinical Relevance: Since SAHA is an FDA-approved HDAC inhibitor (as Vorinostat) for other indications, this study supports the potential for drug repurposing in AATD, potentially accelerating clinical translation.
• Future Directions: The findings highlight the need for further investigation into the post-translational regulation of chaperones (like GRP78) and the specific role of peroxisome pathways in AATD pathogenesis.

In conclusion, this paper establishes a high-fidelity human liver model for AATD, demonstrates the efficacy of SAHA in reducing toxic protein aggregates, and elucidates the molecular mechanisms involving chaperone upregulation and metabolic pathway modulation.